0001103021-22-000004.txt : 20220120 0001103021-22-000004.hdr.sgml : 20220120 20220120080537 ACCESSION NUMBER: 0001103021-22-000004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220120 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220120 DATE AS OF CHANGE: 20220120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC CENTRAL INDEX KEY: 0001103021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352089858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31361 FILM NUMBER: 22540704 BUSINESS ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 BUSINESS PHONE: 919 582 9050 MAIL ADDRESS: STREET 1: 4131 PARKLAKE AVENUE STREET 2: SUITE 225 CITY: RALEIGH STATE: NC ZIP: 27612 FORMER COMPANY: FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP DATE OF NAME CHANGE: 20000111 8-K 1 bdsi-20220120.htm 8-K bdsi-20220120
0001103021FALSE01/20/202200011030212022-01-202022-01-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report: January 20, 2022
 
 BioDelivery Sciences International, Inc.
(Exact name of registrant as specified in its charter)
 
 
Delaware001-31361 35-2089858
(State or other jurisdiction
of incorporation)
(Commission
File Number)
 
(IRS Employer
Identification No.)
4131 ParkLake Ave., Suite 225 
Raleigh,
NC.
27612
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: 919-582-9050
Not Applicable
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
 
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common stock, par value $0.001 BDSI The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 2.02Results of Operations and Financial Condition.

On January 20, 2022, BioDelivery Sciences International, Inc. (the “Company”) issued a press release announcing that its net revenue, BELBUCA net sales and EBITDA for the full year 2021 were expected to come in at the high end of or exceed previously announced guidance. A copy of the press release is being furnished as Exhibit 99.1 to this Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits.
 
(d) Exhibits
Exhibit
No.
  Description
99.1   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 104)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
January 20, 2022 BIODELIVERY SCIENCES INTERNATIONAL, INC.
 By: /s/ John Golubieski
 Name: John Golubieski
 Title: Chief Financial Officer and Treasurer


EX-99.1 2 bdsiq4preannouncement_0120.htm EX-99.1 Document
image_0.jpg
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance

Total 2021 Net Revenue expected in the range of $165 -$167 million, as compared to previous guidance of $162-$167 million

BELBUCA 2021 Net Sales expected to be in the range of $147 -$148 million, as compared to previous guidance of $144-$148 million

2021 EBITDA expected to be in the $40 - $45 million range as compared with previous guidance of <$40 million

RALEIGH, N.C., January 20, 2021 - BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced it expects 2021 total Company net revenues and BELBUCA® (buprenorphine buccal film) net sales to achieve the high end of its previous guidance range, and 2021 EBITDA to come in above its prior guidance range.

“The fourth quarter was transformative for the company on many fronts. Our pain franchise, led by BELBUCA, once again demonstrated resilience in growth and strong cash flow generation, and prevailed in a critical patent case maintaining BELBUCA patent exclusivity against a potential generic competitor through December 2032,” stated Jeff Bailey, CEO of BDSI. “We also continue the commercial planning for ELYXYB™, an FDA-approved drug with substantial peak revenue potential, which represents our broader entry into the neurology market. Looking ahead, we are excited about launching ELYXYB later this quarter, continuing to grow our current core brands, BELBUCA and Symproic®, and potentially benefiting from a growth tailwind as COVID recedes.”

“We grew our BELBUCA revenues, managed operating expenses efficiently in the face of COVID and prepared the groundwork for launching ELYXYB, all while generating approximately $45 to $50 million in EBITDA, excluding ELYXYB launch costs,” said John Golubieski, CFO of BDSI.

“We own three FDA-approved, patented drugs, our cash generation engine is robust, and coupled with our strong balance sheet, should enable us to continue investment in strategic growth drivers and maximize shareholder value,” Mr. Bailey emphasized.

Base Business Remains Strong and Growing

“Despite the impact COVID-19 is having on new patient visits to physicians, we are pleased to see the strong performance of BELBUCA in the fourth quarter,” stated Mr. Bailey. “BELBUCA continues to take market share in the long-acting opioid market, with our total market share now exceeding 5% of the LAO market as of year-end 2021 and achieving record revenues for the fourth quarter of 2021.” BELBUCA remains well positioned as a highly differentiated product in the growing buprenorphine segment of the chronic pain market.
During the fourth quarter of 2021, BELBUCA achieved Total Prescription (TRx) market share of 5.0%, a record for BDSI, and volumes were at an all-time high of 122,000 TRx. For the full year 2021, BELBUCA TRx volumes were up a solid 8.8% year-over-year despite headwinds reported earlier this year.


image_0.jpg
Symproic® (naldemedine) similarly achieved an all-time high 13.0% TRx share and volumes of 19,000 for Q4 2021, an increase of 5.3% year-over-year.
Mr. Bailey added, “Moreover, the use of buprenorphine for chronic pain continued to grow 8.6% year-over-year in 2021. BELBUCA, a Class III (CIII) opioid, provides greater flexibility and convenience to prescribers by allowing multiple refills to be prescribed electronically or called into pharmacies, which is especially advantageous in light of the ongoing pandemic. We anticipate a tailwind for our total BELBUCA net sales growth in 2022, as the Omicron coronavirus variant subsides, and patients begin to reengage with their doctors.
“We announced further good news for our BELBUCA franchise on December 20, 2021, disclosing that we prevailed in litigation against Alvogen, preventing it from entering the market until 2032. This important court decision validates our patent portfolio and enhances the long-term value of BELBUCA.”
Migraine Opportunity
In the fourth quarter, the Company prepared for the upcoming launch of ELYXYB, the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. “This will be our first entry into the adjacent and complementary market of neurology, representing a new source of future revenue growth. With projected peak sales outlook of $350-$400 million, including potential pediatric label expansion, we are excited to launch it into the growing $1.9 billion migraine market,” stated Scott Plesha, President and Chief Commercial Officer.
“We are enthusiastic to see our differentiated products continue to achieve record levels for both the fourth quarter and full year 2021, reflecting persistent excellent execution by the Company’s sales and marketing teams,” said Mr. Plesha. “The launch of ELYXYB will primarily leverage our existing sales force and marketing group without burdening our organization with significant expense, offering a strategic, cost-effective entry to the large and growing migraine market. We will be making a balanced investment behind ELYXYB, as part of our portfolio of commercial products. We are pleased with the positive reception by headache specialists and payors from our discussions on ELYXYB, which is the first and only liquid, ready-to-use product in the migraine market.”
Updated full year 2021 Guidance
Total Company Net Revenue for 2021 is expected to be in the range of $165-$167 million, compared to previous guidance of $162-$167 million.
BELBUCA Net Sales for 2021 are expected to be in the range of $147-$148 million, compared to previous guidance of $144-$148 million.
Total Operating Expenses for 2021 are expected to be in the range $106 - $110 million, as compared to previous guidance of $115 - $120 million, including pre-launch investments to support the first quarter 2022 launch of ELYXYB. 

EBITDA for the full-year 2021 is expected to be in the $45 - $50 million range, excluding the Company’s pre-launch investment for ELYXYB, and is at the upper end of previous guidance of $40 - $50 million. Full-year 2021 EBITDA, including the pre-launch investment for ELYXYB, is expected to be in the $40 - $45 million range as compared with previous guidance of <$40 million.




image_0.jpg
ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated pain and neurology products and leverages its experienced sales and marketing organization to educate prescribers on their unique features. BDSI's products address serious and debilitating conditions, including chronic pain, acute migraine and opioid-induced constipation.

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS
This press release and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. (“BDSI”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to BDSI’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of BDSI’s management and are subject to significant risks and uncertainties, including those detailed in BDSI’s filings with the Securities and Exchange Commission. Actual results including, without limitation, the expectations for: 2021 total Company net revenues, Belbuca net sales, total operating expenses and EBITDA, launch of ELYXYB in the first quarter of 2022 and continued Belbuca patent exclusivity through 2032, may differ materially from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond BDSI’s control) including the risk that the current COVID-19 pandemic impacts on our supply chain, commercial partners, patients and their physicians and the healthcare facilities in which they work, and our personnel are greater than we anticipate, as well as those set forth in our 2020 annual report on Form 10-K filed with the US Securities and Exchange Commission and subsequent filings. BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States, or GAAP, including EBITDA. This non-GAAP measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to similar measures presented by other companies.
EBITDA excludes net interest, including both interest expense and interest income, provision for (benefit from) income taxes, depreciation, and amortization.
The Company's management and board of directors utilize this non-GAAP financial measure to evaluate the Company's performance. The Company provides this non-GAAP measure of the Company's performance to investors because management believes that this non-GAAP financial measure, when viewed with the Company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, EBITDA is not a measure of financial


image_0.jpg
performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, EBITDA should not be considered a measure of our liquidity.
ELYXYB INDICATION AND USAGE
ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.
Limitations of Use: ELYXYB is not indicated for the preventive treatment of migraine.

ELYXYB IMPORTANT SAFETY INFORMATION
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
Cardiovascular Thrombotic Events
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use [see Warnings and Precautions (5.1)].
ELYXYB is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)].
Gastrointestinal Bleeding, Ulceration, and Perforation
NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious (GI) events [see Warnings and Precautions (5.2)].

ELYXYB is contraindicated in patients with:
Known hypersensitivity to celecoxib, any components of the drug product, or sulfonamides (4)
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4)
In the setting of CABG surgery (4)
To minimize the potential risk for an adverse cardiovascular (CV) event in NSAID-treated patients, use ELYXYB for the fewest number of days per month as needed, based on individual treatment goals. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
Avoid the use of ELYXYB in patients with a recent myocardial infarction (MI) unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ELYXYB is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.
NSAIDs, including ELYXYB, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with celecoxib. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.


image_0.jpg
Avoid the use of ELYXYB in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ELYXYB is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs, including ELYXYB.
Long-term administration of NSAIDs, including celecoxib, the active ingredient in ELYXYB, has resulted in renal papillary necrosis and other renal injury.
No information is available from controlled clinical studies regarding the use of celecoxib in patients with severe renal impairment. The renal effects of celecoxib may hasten the progression of renal dysfunction in patients with preexisting renal disease.
Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, nonsteroidal anti-inflammatory drugs or combination of these drugs for 10 or more days per month), including ELYXYB, may lead to exacerbation of headache (medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients, including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.
NSAIDs, including ELYXYB, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.
Most common adverse reaction (at least 3% and greater than placebo) is dysgeusia.
These are not all the side effects associated with ELYXYB.
Please see Patient Information, Instructions For Use, Medication Guide and Full Prescribing Information for ELYXYB
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212157s000lbl.pdf)

© 2022 BioDelivery Sciences International, Inc. All rights reserved.
Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

EX-101.SCH 3 bdsi-20220120.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 bdsi-20220120_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 bdsi-20220120_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 image_0.jpg begin 644 image_0.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 20, 2022
Cover [Abstract]  
Document Type 8-K
Entity Registrant Name BioDelivery Sciences International, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-31361
Entity Tax Identification Number 35-2089858
Entity Address, Address Line One 4131 ParkLake Ave., Suite 225
Entity Address, City or Town Raleigh,
Entity Address, Postal Zip Code 27612
City Area Code 919
Local Phone Number 582-9050
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001
Trading Symbol BDSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Amendment Flag false
Document Period End Date Jan. 20, 2022
Entity Address, State or Province NC
Entity Central Index Key 0001103021
XML 8 bdsi-20220120_htm.xml IDEA: XBRL DOCUMENT 0001103021 2022-01-20 2022-01-20 0001103021 false 2022-01-20 8-K BioDelivery Sciences International, Inc. DE 001-31361 35-2089858 4131 ParkLake Ave., Suite 225 Raleigh, NC 27612 919 582-9050 false false false false Common stock, par value $0.001 BDSI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://bdsi.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bdsi-20220120.htm bdsi-20220120.xsd bdsi-20220120_lab.xml bdsi-20220120_pre.xml bdsiq4preannouncement_0120.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bdsi-20220120.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "bdsi-20220120.htm" ] }, "labelLink": { "local": [ "bdsi-20220120_lab.xml" ] }, "presentationLink": { "local": [ "bdsi-20220120_pre.xml" ] }, "schema": { "local": [ "bdsi-20220120.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bdsi", "nsuri": "http://bdsi.com/20220120", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20220120.htm", "contextRef": "ie560874278364e2d900a0192dc231c37_D20220120-20220120", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://bdsi.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdsi-20220120.htm", "contextRef": "ie560874278364e2d900a0192dc231c37_D20220120-20220120", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bdsi.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001103021-22-000004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001103021-22-000004-xbrl.zip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end